Masimo Corporation (MASI)

The most significant event impacting Masimo's stock price in the past six months is the announced acquisition by Danaher Corporation for $180.00 per share in cash, totaling approximately $9.9 billion, which was approved by shareholders on May 1, 2026, and is expected to close in the second half of 2026. Masimo reported strong third-quarter 2025 results, with GAAP revenue of $371.5 million and non-GAAP diluted EPS of $1.32, exceeding forecasts. Masimo completed the sale of its non-healthcare consumer audio business, Sound United, to Harman International Industries, using the net proceeds for stock repurchases. Analysts have issued price targets for MASI, with a median target of $187.0.

Masimo's products and services experience some demand seasonality, particularly within its healthcare segment. Healthcare revenues in the third quarter of the fiscal year have historically represented a lower percentage of segment revenues due to summer vacation schedules. Demand for Masimo's products could decrease significantly during a recession. The timing of the flu season can also impact demand.

Masimo Corp. is a global medical technology company focused on noninvasive patient monitoring technologies. The company operates through healthcare and non-healthcare segments. The healthcare segment offers noninvasive patient monitoring technologies, hospital automation solutions, remote monitoring devices, and consumer health products, including Masimo SET® Pulse Oximetry, Masimo Rainbow SET™ Pulse CO-Oximetry, Brain Function Monitoring, Capnography and Gas Monitoring, Hospital Automation and Connectivity Solutions, and Wearable Devices. Masimo completed the sale of its Sound United consumer audio business to Harman International in the third quarter of 2025.

Masimo Corporation has a significant global presence, with operations and distribution networks spanning the Americas, Europe, Asia, the Middle East, Africa, and Australia. The United States is a primary market, accounting for approximately 60% of total healthcare revenue in 2025. The company has strong brand recognition across North America and Western Europe and is expanding in Asia-Pacific and emerging markets. Masimo's products are used in over 150 countries. Its headquarters are located in Irvine, California, USA, with an international headquarters in Neuchâtel, Switzerland.

Masimo's brand reputation has been significantly influenced by its technological innovations and a high-profile patent dispute. The United States International Trade Commission (ITC) ruled that Apple Inc. had infringed patents held by Masimo related to light-based pulse oximetry in the Apple Watch product line. Masimo's Signal Extraction Technology (SET®) pulse oximetry is widely recognized and used as the primary pulse oximetry technology in many leading hospitals globally. The expansion of its strategic partnership with Philips further enhances its reputation and market reach.

Masimo Corporation's ownership is primarily held by institutional investors, with a notable stake also maintained by its founder. Major institutional owners include BlackRock, Inc., FMR LLC (Fidelity), Vanguard Group Inc., Politan Capital Management LP (Quentin Koffey), State Street Corporation, Massachusetts Financial Services Co /ma/, and T. Rowe Price Investment Management, Inc. Joe Kiani, the founder, maintains a notable stake in the company.